Abstract: The present invention provides methods and compositions for treating advanced stage non-small cell lung cancer by cyclohexenone compounds.

Abstract: A microbe-resistant coating, coating intermediate, finish, finish intermediate, or colorant that includes an antimicrobial agent. The antimicrobial agent is an inorganic bismuth-containing compound, and may be used in conjunction with other bismuth-containing compounds or other biocidal agents or methods. The bismuth-containing compound may also be used to impart micro-resistance to a coating, coating intermediate, finish, finish intermediate, colorant, processing equipment or vessels.

Abstract: A nasally administered liquid, including suspension and viscous liquid compositions, containing a therapeutically effective quantity of (Z)-2-(3,5,5-trimethyl-2-cyclohexen-1-ylidene) acetic acid, its salts or analogs, combined with suitable pharmaceutical ingredients, to treat epilepsy.

Abstract: The present invention is directed to therapeutic compositions for treating pancreatic cancer comprising a cyclohexnone compound and one or more anti-cancer agents.

Abstract: The present invention provides methods and compositions for treating atopic dermatitis by cyclohexenone compounds.

Abstract: The present invention provides an ophthalmic composition and a use thereof. In one embodiment of the present invention, an ophthalmic composition containing a clathrated antioxidant substance is provided. In some of embodiments of the present invention, a composition for treating or preventing an ophthalmic disease, an ophthalmic disorder or an ophthalmic symptom is provided, wherein the ophthalmic disease, the ophthalmic disorder or the ophthalmic symptom includes, but is not limited to, dry eye or a dry eye-like ophthalmic disease, conjunctivitis, corneal ulcer, age-related macular degeneration, cataract, pseudoexfoliation syndrome, and symptoms in these diseases which can be ameliorated by increasing the quantity of tears and/or goblet cells and/or mucin.

Abstract: Provided is a process for extraction of a lipophilic agent from a plant source, the process including: mixing a first quantity of a plant source, the plant source being containing the lipophilic agent and a first quantity of an extraction medium to obtain a first mixture, the extraction medium being in the form of a microemulsion and comprising at least one oil, at least one hydrophilic surfactant, at least one co-surfactant and optionally at least one co-solvent; homogenizing the first mixture under conditions maintaining the microemulsion structure; and separating the homogenized mixture into a biomass slurry and an agent-loaded medium to obtain the agent-loaded medium in a microemulsion form.

Abstract: Methods and formulations for treating oncological disorders in humans using Coenzyme Q10 are described.

Abstract: 2-Dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione (DMDD), as well as variants, derivatives, analogs, modifications, and conjugates thereof, are identified as therapeutic agents for treating or preventing human cancers and precancerous conditions. DMDD can be isolated from the root of Averrhoa carambola L., commonly known as starfruit. Pharmaceutical and nutraceutical compositions, as well as dietary supplements, are provided, as are methods of administration and treatment.

Abstract: A series of benzosuberene analogues demonstrate effective inhibition of tubulin polymerization, cytotoxicity against human cancer cell lines, and vascular disruption in tumors.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention provides methods for treating glomerulosclerosis such as focal segmental glomerulosclerosis (FSGS) or glomerulonephritis such as immunoglobulin A nephropathy (IgAN) by cyclohexenone compounds.

Abstract: The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.

Abstract: The present invention relates to methods of treating Leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.

Abstract: A method of parenterally administering a composition, the method including parenterally administering to a person a composition including krill oil in an oil-in-water emulsion. A parenterally applicable pharmaceutical composition, including an oil-in-water emulsion including a phospholipid obtained from a marine crustacean.

Abstract: The subject invention concerns a compound and compositions having activity as an inhibitor of Stat3 protein and methods of using the compound and compositions. In one embodiment, a compound of the invention has the structure shown in formula I, formula II, or formula III. The subject invention also concerns methods of using the compounds and compositions of the invention.

Abstract: The invention relates to bioactive compounds purified from mycelium of Antrodia camphorata and the manufacturing method thereof. A method for treatment of cancers by administrating an effective amount of the said compounds selected from the group consisting of AC006, AC007, AC009, AC011, AC012, AC007-H1, AC009-H1, and AC012-H1 wherein the cancers is liver cancer, brain cancer, prostate cancer, breast cancer, colorectal cancer, or melanoma.

Abstract: The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR?, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPAR? modulation such as diabetes.

Abstract: The present invention relates to novel cannabidiol quinone derivatives of formula (I) (I) wherein R is the carbon atom of a, linear or branched group, represented by: alkyl, aryl, alkenyl, alkynyl, acyl or alkoxycarbonyl groups; or wherein R is the nitrogen atom of a, linear or branched group represented by: alkylamine, arylamine, alkenylamine or alkynylamine groups. The invention also relates to the use of any of the compounds of formula (I) as medicaments in therapy, particularly for treating diseases and conditions responsive to PPARg modulation due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.

Abstract: The present invention relates to a method or composition for treating diabetes mellitus, comprising administering a subject with a pharmaceutical composition comprising a therapeutically effective amount of an active compound from Antrodia camphorate, such as antroquinonols, and a pharmaceutically acceptable carrier. In addition, the prevent invention provides a new process for the total synthesis of antroquinonol. Also provided are the new compounds produced during the process for preparing of antroquinonol.

Abstract: The disclosure provides a method for modulating Th17 cells, including: administering an Antrodia cinnamomea (also named Antrodia camphorata or Taiwanofungus camphoratus) extract to a subject in need thereof, wherein the Antrodia cinnamomea extract has an effect of modulating Th17 cells. The Antrodia cinnamomea extract may include a fruiting body extract of Antrodia cinnamomea or a mycelium extract of Antrodia cinnamomea.

Abstract: Killing of bed bugs is accomplished by bringing the bed bugs into contact with a toxic amount of at least one of the compounds of the structure (I) wherein X is —OH, ?O, or —O(O)CR, wherein R is selected from H and a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to three double bonds and from 1 to 11 carbon atoms; R1 is H or CH3; R2 is H or CH3; R3 is H or a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to three double bonds and from 1 to 11 carbon atoms; and wherein the compounds of structure (I) contain from 6 to 20 total carbon atoms in the compounds.

Abstract: A composition for use in inhibiting or killing Porphyromonas gingivalis, comprising an effective amount of Antrodia camphorata powder or extract and acceptable carriers thereof for inhibiting or killing Porphyromonas gingivalis. Also provided is a method of inhibiting or killing Porphyromonas gingivalis by using aforementioned composition. Further provided is a method of alleviating or treating diseases derived from Porphyromonas gingivalis by administrating a therapeutically effective amount of aforementioned composition. The Antrodia camphorata extract in accordance with the present invention have been proved having the efficacy of inhibiting or killing Porphyromonas gingivalis, and thus can be easily applied to various fields, particularly, health foods, drinks and applications of daily supplies. Moreover, advantages in accordance with the present invention include no side effects, easy fabricating and low cost.

Abstract: Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.

Abstract: The present invention relates to a process of preparing tocotrienol quinones. It has been found that this process allows the formation of the R-isomer in a high yield in a very efficient and economically interesting way. Said process is particularly useful when implemented in an industrial process. Furthermore, it has been found that this process allows using isomer mixtures as they result from traditional industrial synthesis.

Abstract: The present invention teaches a combination of specific nutrients suitable for oral consumption by the human body. The compositions of the present invention when orally ingested on a daily basis, work to aid the in slowing or eliminating, or reversing the progression of the respiratory diseases. It is believed that the key ingredients of the present invention work synergistically together to aid in the slowing, stopping, or reversing the symptoms and metabolic disorder characteristic of the human asthmatic or allergenic condition. The essential components of the present invention are Barley Grass Juice Powder, Green Tea Extract, Grape Seed Extract, Citrus Bioflavonoid, Selenium, Vitamin D3, Vitamin C, Vitamin E, Vitamin B6, Zinc, EPA, DHA, Lycopene, l-Carnitine, Coenzyme Q10, Folic Acid, and Magnesium.

Abstract: A concussive injury micronutrient formulation is provided and the formulation comprises vitamin A, vitamin E, natural mixed carotenoids, vitamin C, vitamin D, coenzyme Q10, alpha-lipoic acid, N-acetyl cysteine, acetyl L-carnitine (fumarate), vitamin B, folic acid, calcium, magnesium, selenium, chromium, biotin, zinc, and omega-3 fatty acids.

Abstract: The present invention relates to a thermo-responsive hydrogel polymer formulated with one or more active agents selected from the group consisting of menthol and menthone, wherein said active agents are effective in invigorating the user and/or effective in relieving fatigue.

Abstract: Control or repellency of mosquitoes is accomplished by bringing the insects into contact with at least one of the compounds of the structure (I) wherein R is selected from —OH, ?O, —OC(O)R4, —OR6, —(OR6)2, wherein each R6 is independently selected from an alkyl group containing from 1 to 4 carbon atoms and R4 is a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; X is O or CH2, with the proviso that when X is O R can only be ?O; each Z is independently selected from (CH) and (CH2); y is a numeral selected from 1 and 2; R1 is selected from H or a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; R2 is selected from H and a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to three double bonds and from 1 to 15 carbon atoms; R3 is selected from the group consisting of H and a branched or straight chain, satur

Abstract: Compounds are used in compositions as antimicrobial agents against microbes, such as for example, Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Pseudomonas aeruginosa, Candida albicans, and Aspergillus brasiliensis. Antimicrobial action is obtained by contact of a microorganism with at least one of the compounds of the structure (I); wherein R is a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero or one double bond and a total of from 1 to 11 carbon atoms; R1 is —OH, =0 or —OC(0)CH3 and wherein the compounds of structure (I) contain a total of from 9 to 18 carbon atoms in the compounds.

Abstract: A method of constructing a data architecture for use in identifying connections between perturbagens and genes associated with a type of periorbital dyschromia. The method includes providing a gene expression profile for a keratinocyte, fibroblast, melanocyte or melanoma cell, which has been exposed to at least one perturbagen, and comparing the gene expression profile to a control cell from the same cell line. Genes that are differentially expressed in response to the perturbagen are identified by comparing the gene expression profiles of the control cell and the test cell. An ordered list of identifiers representing the differentially expressed genes is created according to the differential expression of the genes. The ordered list is stored as an instance on a computer readable medium. The steps are then repeated to construct a data architecture of stored instances.

Abstract: The present invention relates to the use of at least one cyclohexanol ether derivative of the formula I as antimicrobial active compound or as anti-acne, antidandruff, deodorant or antiperspirant active compound, to preparations comprising these compounds, and to specific cyclohexanol ether derivatives.

Abstract: A treatment protocol for use in the treatment of neurocutaneous syndrome is described and comprises at least one xanthone component, which may comprise at least one mangosteen component, and at least one detoxification component. Additional embodiments comprise at least one herbal component, at least one vitamin component, or a combination thereof. A method of treating a patient having neurocutaneous syndrome is described herein and comprises: providing at least one xanthone component, which may comprise at least one mangosteen component, providing at least one xanthone component, which may comprise at least one mangosteen component, to the patient, and administering the at least one detoxification component to the patient. Additional methods steps may include providing and administering at least one herbal component, providing and administering at least one vitamin component or a combination thereof.

Abstract: A method of inhibiting excitotoxicity by indirectly activating ?4?2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed Inhibitors of ?7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate ?4?2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis.

Abstract: This invention is directed to an ameliorating agent for a disease based on vesicourethral dyssynergia, comprising, as an active ingredient, 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexene-1-one, a salt thereof, or a solvate thereof. The disease based on vesicourethral dyssynergia is any of dysuria accompanying a lifestyle-related disease (such as diabetic dysuria), idiopathic dysuria, dysuria after pelvic surgery, dysuria accompanying spinal cord injury, dysuria accompanying spinal canal stenosis, dysuria accompanying benign prostatic hypertrophy, dysuria accompanying high-pressure voiding/high-pressure urine storage, neurogenic or nonneurogenic lower urinary tract symptoms (LUTS), detrusor sphincter dyssynergia, and detrusor bladder neck dyssynergia.

Abstract: Disclosed are compounds that inhibit RNase H activity of retroviruses, for example, a compound of formula (I) wherein R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment or prevention of infection by human immunodeficiency virus (HIV).

Abstract: Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.

Abstract: Activated fatty acids, nutraceutical compositions including activated fatty acids, methods for using activated fatty acids to treat a variety of diseases, and methods for preparing activated fatty acids are provided herein.

Abstract: A method for inhibiting or preventing metastasis of breast tumor cells in a subject is disclosed. The method includes administering to the subject an effective amount of a compound of formula (I). In formula (I), R is H or methyl.

Abstract: A nutritional supplement for inhibiting sensorineural hearing loss includes from about 0.25 to about 6.0 wt. % thiamin, from about 0.1 to about 10 wt. % pyridoxiyl-5-phosphate, from about 0.01 to about 10 wt. % folic acid, from about 0.025 to about 4.0 wt. % hydroxycobalamin, from about 1 to about 7 wt. % magnesium, from about 0.25 to about 6.0 wt. % zinc, from about 0.001 to about 0.02 wt. % selenium, from about 0.1 to about 10 wt. % manganese, from about 5 to about 50 wt. % ginger root P.E. 4:1, from about 5 to about 40 wt. % citrus bioflavonoids, from about 2.5 to about 40 wt. % 1-cystine, from about 5 to about 40 wt. % n-acetlyl-1-carnitine, from about 1 to about 40 wt. % alpha lipoic acid, from about 1 to about 40 wt. % coenzyme Q10, from about 1 to about 40 wt. % green tea extract, and from about 1 to about 60 wt. % resveratrol.

Abstract: The present invention provides methods and compositions for treating arteriosclerotic vascular diseases by cyclohexenone compounds. In some embodiments, the compound in the methods inhibits PDGF-stimulated smooth muscle cell proliferation or migration. In some embodiments, the atherosclerosis is associated with coronary artery disease, aneurysm, arteriosclerosis, myocardial infarction, embolism, stroke, thrombosis, angina, vascular plaque inflammation, vascular plaque rupture, Kawasaki disease, calcification or inflammation. In some embodiments, the compound lowers low-density lipoprotein (LDL) cholesterol in the subject. In some embodiments, the compound maintains a normal low-density lipoprotein (LDL) cholesterol level in the subject.

Abstract: The present invention concerns an antiviral composition comprising the following components: R-(?)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called (?) carvone) and S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called (+) carvone) and (2E)-3,7-dimethylocta-2,6-dien-1-ol (also called trans-geraniol) in combination with at least one more component chosen among essential oils components for use in treatment and prevention of diseases caused by DNA enveloped viruses, DNA non-enveloped viruses, RNA enveloped viruses and RNA non-enveloped viruses.

Abstract: According to the present invention, there are provided a food and a food additive obtained using an alkaline decomposition product of a hop extract, and an agent for suppressing fat accumulation or for suppressing weight gain comprising the same as an active ingredient.

Abstract: The invention relates to compositions and methods for regulating hair growth. Specifically, the invention relates to regulating hair growth by regulating the activity one of the prostaglandin D2 (PGD2) receptors, DP-2 (GPR44). Compositions and methods for regulating hair growth include inhibiting hair growth by administering a DP-2 agonist, or stimulating hair growth by administering a DP-2 antagonist.

Abstract: Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD—not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.

Abstract: The present invention relates to methods of treating methylmalonic aciduria and other organic acidurias with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.

Abstract: The present invention is directed to anti-microbial cleanser compositions comprising linalool, hinokitiol and dipropylene glycol. The present invention further provides methods for using these compositions to maintain eyelid hygiene, to treat an ocular disorder or to clean a skin surface. The cleanser compositions of the present invention can be in the form of a foam, gel or liquid.

Abstract: Disclosed herein are methods of using nutritional supplements and specific combinations thereof to counteract exercise-induced inflammation in monogastric organisms. Particular embodiments focus on use of quercetin, curcumin, boswellia, CoQ10, ribose, calcium carbonate, and zinc and their variants. Methods include ascertaining and modifying the nutritional supplements, ascertaining and comparing health states of all performance athletes, wherein the comparisons are made before and after modifications of the supplements and/or implementation of exercise regimens.

Abstract: The present invention provides pharmaceutical and dietary compositions in which pyrroloquinoline quinone (PQQ) and its derivatives are combined with other biologically active compounds to produce a synergistic beneficial effect beyond the effect produced by PQQ or its derivatives alone. The present invention also provides methods for providing various beneficial effects which comprise administering these compositions to a mammalian subject.

Abstract: Compounds are used as agents that deter feeding of crops by agricultural pests such as hemiptera, lepidoptera and coleoptera, including, but not limited to, stink bugs, codling moth larvae and granary weevils.